What We're Reading
Industry reads hand-picked by our editors
Jul 27, 2026
-
The Wall Street Journal
The Scientist With 1,000 Patents Fueling a Drug Powerhouse
-
The Washington Post
Peptide boom has states scrambling to protect consumers, Post investigation finds
-
Nature
Bizarre CRISPR enzyme kills cancer cells by shredding their DNA
Jul 24, 2026
Jul 23, 2026
Jul 22, 2026
Jul 21, 2026
Jul 20, 2026
-
Axios
How AI is supercharging drug development
-
The Financial Times
AstraZeneca highlights rare diseases in $80bn revenue push
-
Chemical & Engineering News
Access to potential long COVID drugs dwindles as trials falter
-
CNBC
The market for psychedelic drugs to treat mental health conditions gets a big buy signal
Jul 17, 2026
-
NPR
TrumpRx promised a supermarket for cheaper drugs but delivered a boutique
-
BioSpace
FDA’s first AI-focused cGMP warning letter signals new scrutiny for manufacturers
-
The Washington Post
CDC, FDA link Taco Bell lettuce supplier to multistate cyclosporiasis outbreak
-
MIT Technology Review
There’s a lot of hype around perimenopause. Don’t buy it.
